Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metagenomi
Biotech
Metagenomi axes ALS program after seeing Biogen and Ionis flop
Metagenomi is seeking a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis activities in response to rivals' setbacks.
Nick Paul Taylor
Aug 14, 2024 9:20am
Moderna exits Metagenomi gene editing deal worth $3B biobucks
May 1, 2024 4:00pm
Metagenomi, Telomir offer double test case for preclinical IPOs
Feb 9, 2024 7:00am
Kyverna raises IPO expectations to almost $300M
Feb 6, 2024 9:46am
Gene editing biotech Metagenomi plans modest $87M IPO
Feb 5, 2024 9:14am
Arrivent unveils $135M IPO pricing to get furmonertinib to FDA
Jan 22, 2024 10:28am